H.C. Wainwright lowered the firm’s price target on Nuvation Bio (NUVB) to $10 from $11 and keeps a Buy rating on the shares following the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio Reports Transformative Year in 2024
- Nuvation Bio Positioned for Growth: Buy Rating Affirmed on Strategic Moves and Promising Drug Pipeline
- Nuvation Bio files automatic mixed securities shelf
- Nuvation Bio reports Q4 EPS (15c), two estimates (12c)
- RBC bullish on Nuvation as royalty deal, non-dilutive financings remove overhang